Navigation Links
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Date:8/22/2007

ders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements" regarding the timing and progress of Nuvelo's clinical programs, including the timing of the availability of data from Nuvelo's Phase 3 alfimeprase trials, the potential improvement or benefit that current and future clinical trial programs may demonstrate, and our anticipated revenues, operating expenses and net cash used in operations, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo fi
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015 Velos, Inc., the pioneering software ... grow and add customers who receive Clinical and Translational ... CTSAs awarded by the National Institutes of Health currently ... is among the largest such market shares in its ... CTSA community keeps growing as a result of our ...
(Date:6/30/2015)... , June 30, 2015   Millar, Inc. ... technology, today announced the 2016 retirement of Craig ... Directors, after 12 years of service to the Company. ... named two senior members of the Executive Management team ... Tim Daugherty , currently Director of Sales and ...
(Date:6/30/2015)... , June 30, 2015 Olympus, ... innovative solutions for medical and surgical procedures, among ... next-day replacements for surgical equipment at no additional ... to offer this type of guarantee. The service ... Service Agreement earlier this year. ...
Breaking Medicine Technology:Velos continues adding CTSA customers - 40% now use Velos products 2Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3
... 7, 2010 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Review meeting with the U.S. Food and Drug Administration (FDA) ... the Company,s New Drug Application (NDA) for AZ-004 ( Staccato ... FDA in preparation for the meeting, with the responses or ...
... Dec. 7, 2010 Apexigen, Inc. announced today ... worldwide license agreement with Centocor Research & Development, ... therapeutic antibody technologies to discover and develop monoclonal ... to several targets specified by Centocor R&D, which ...
Cached Medicine Technology:Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine) 2Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine) 3Apexigen, Inc. Announces Collaboration for Antibody Discovery 2
(Date:7/1/2015)... ... ... Recent research has revealed that most adults lack confidence in the effectiveness ... Starting the last Monday of June, Whiter Image Dental will help new ... the customer’s first popular In-Office 2 Patient Kit. , The In-Office ...
(Date:7/1/2015)... Windsor, Vermont (PRWEB) , ... July 01, 2015 ... ... systems based in Windsor, Vermont, is partnering with Mexican based water fountain manufacturer, ... children throughout Mexico. Vermont Senator Patrick Leahy, who is ranked among the top ...
(Date:6/30/2015)... California (PRWEB) , ... July 01, 2015 , ... Avid ... for 1968 Doors and Jimi Hendrix Singer Bowl concert posters. The Who and the Rascals ... August 2. According to Hawley, "The Doors played with the Who backing them ...
(Date:6/30/2015)... ... ... Carey Danis & Lowe comments on a new pretrial order ... court. The court document outlined the judge’s plan to consolidate 26 vaginal mesh lawsuits. ... & Lowe is a personal injury law firm with headquarters in St. Louis. The ...
(Date:6/30/2015)... Shippensburg, PA (PRWEB) , ... June 30, 2015 , ... ... affected by cardiovascular disease, cancer, autism, dementia, auto-immune deficiencies, or obesity. Why? , The ... , Dr. Pete Sulack, America’s Leading Stress Expert, has successfully treated over one ...
Breaking Medicine News(10 mins):Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2Health News:Clean Drinking Water Now Available to Millions of Mexican Children as a Result of Partnership Between Seldon Technologies and Bebederos Ecologicos / Ottone Meloda 2Health News:Clean Drinking Water Now Available to Millions of Mexican Children as a Result of Partnership Between Seldon Technologies and Bebederos Ecologicos / Ottone Meloda 3Health News:Avid Boxing Style Rock Concert Poster Collector From Vintage Rock Posters Announces Search for 1968 Doors and Jimi Hendrix Singer Bowl Concert Posters 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2
... one of them has developed a flesh eating disease; another ... ,Necrotising fasciitis (flesh eating disease) is a rare infectious, ultimately ... spent five weeks in the hospital, and is released now. ... to the officials that the tattooist has to improve the ...
... discovered a protein interaction that may explain how the ... in and featured on the cover of the current ... Huntington’s protein interacts with another protein to cause dramatic ... ,“Cholesterol is essential for promoting the connection network among ...
... could help in fighting cancer,// a recent study issued an ... prone to a relapse of caner in the following cases: ... stem cells are from a female donor. ,This second ... the original transplant. This is more pronounced in them than ...
... Gene Therapy has published the findings of the first ... dysfunction.// The finding shows that gene therapy negates the ... beneficial for months, and hence could be the most ... author Arnold Melman, M.D., professor and chair of the ...
... has shown, in India, a majority of married women are ... Therefore, there is a definite need for protective methods that ... male-controlled methods are not even 20 percent helpful. ,A ... by over-the-counter microbicides, which are gels, creams, films, or suppositories, ...
... been told that patients undergoing chemotherapy in remote areas may ... the patient sending a text of his symptoms according to ... means of a red alert sent to medical staff, or ... of new age technology may be used along with a ...
Cached Medicine News:Health News:Link Between Huntington’s and Abnormal Cholesterol Levels in Brain Establishe 2Health News:The Other Side of Hematopoietic Stem Cell Transplant 2Health News:Gene Therapy May Be the Solution for Erectile Dysfunction 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: